Ascletis Pharma Inc. (1672.HK)
1672.HK Stock Price Chart
Explore Ascletis Pharma Inc. interactive price chart. Choose custom timeframes to analyze 1672.HK price movements and trends.
1672.HK Company Profile
Discover essential business fundamentals and corporate details for Ascletis Pharma Inc. (1672.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Aug 2018
Employees
231.00
Website
https://www.ascletis.comCEO
Jinzi Jason Wu
Description
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.
1672.HK Financial Timeline
Browse a chronological timeline of Ascletis Pharma Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 15 Aug 2025
EPS came in at -$0.10 surpassing the estimated -$0.14 by +29.69%, while revenue for the quarter reached $1.18M .
Earnings released on 23 May 2025
Earnings released on 26 Mar 2025
EPS came in at -$0.10 surpassing the estimated -$0.16 by +40.08%, while revenue for the quarter reached $709.86K .
Earnings released on 31 Dec 2024
EPS came in at -$0.09 , while revenue for the quarter reached $682.43K .
Earnings released on 30 Aug 2024
EPS came in at -$0.07 surpassing the estimated -$0.13 by +46.61%.
Earnings released on 23 May 2024
EPS came in at -$0.07 .
Earnings released on 26 Mar 2024
EPS came in at -$0.06 surpassing the estimated -$0.07 by +7.49%, while revenue for the quarter reached $5.41M , missing expectations by -76.24%.
Earnings released on 31 Dec 2023
EPS came in at -$0.07 , while revenue for the quarter reached $5.58M .
Earnings released on 22 Aug 2023
EPS came in at -$0.01 surpassing the estimated -$0.08 by +89.13%, while revenue for the quarter reached $26.54M , missing expectations by -47.18%.
Earnings released on 30 Jun 2023
EPS came in at -$0.01 , while revenue for the quarter reached $25.15M .
Earnings released on 20 Mar 2023
EPS came in at -$0.11 surpassing the estimated -$0.17 by +32.50%, while revenue for the quarter reached $8.72M , missing expectations by -89.91%.
Earnings released on 31 Dec 2022
EPS came in at -$0.12 , while revenue for the quarter reached $9.04M .
Earnings released on 22 Aug 2022
EPS came in at -$0.05 surpassing the estimated -$0.08 by +39.15%, while revenue for the quarter reached $23.55M , missing expectations by -60.41%.
Earnings released on 30 Jun 2022
EPS came in at -$0.05 , while revenue for the quarter reached $22.37M .
Earnings released on 22 Mar 2022
EPS came in at -$0.05 surpassing the estimated -$0.11 by +56.08%, while revenue for the quarter reached $24.32M , missing expectations by -40.86%.
Earnings released on 31 Dec 2021
EPS came in at -$0.05 , while revenue for the quarter reached $24.69M .
Earnings released on 27 Aug 2021
EPS came in at -$0.06 surpassing the estimated -$0.08 by +28.03%, while revenue for the quarter reached $21.94M , missing expectations by -30.56%.
Earnings released on 31 Mar 2021
EPS came in at -$0.06 , while revenue for the quarter reached $21.64M .
Earnings released on 30 Mar 2021
EPS came in at -$0.09 falling short of the estimated -$0.01 by -720.00%, while revenue for the quarter reached $1.88M , missing expectations by -98.66%.
Earnings released on 29 Mar 2021
EPS came in at -$0.09 falling short of the estimated -$0.01 by -687.27%, while revenue for the quarter reached $1.81M , missing expectations by -98.71%.
1672.HK Stock Performance
Access detailed 1672.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.